Medtronic (NYSE:MDT) and Intarcia Therapeutics were in the spotlight at the American Diabetes Assn.’s annual scientific sessions conference in Boston last week, revealing new medical device developments in the fight against diabetes. Medtronic took center stage, announcing new developments for its artificial pancreas program, touting positive data from a user study of its MiniMed 640g and revealing plans to collaborate […]
Intarcia Therapeutics
Intarcia adds $225m for Type II diabetes trial
Intarcia Therapeutics yesterday took its total raise to more than $1 billion with a $225 million funding round it plans to use to run clinical trials and commercialize its the drug-device combination treatment it’s developing for Type II diabetes.
Diabetes: Intarcia inks $1B development deal with Servier
Intarcia Therapeutics said today that French pharmaceutical independent Servier agreed to a deal to commercialize Intarcia’s implantable diabetes pump that could be worth some $1 billion.
